10-Year Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Calculation   in Out-Patient Department

Authors

  • Hafiz Waleed Khan Department of Medicine, Combined Military Hospital Malir /National University of Medical Sciences (NUMS) Pakistan
  • Muhammad Imran Department of Medicine, Combined Military Hospital Malir /National University of Medical Sciences (NUMS) Pakistan
  • Samia Khan Department of Medicine, Combined Military Hospital Malir /National University of Medical Sciences (NUMS) Pakistan
  • Muhammad Hammad Athar Department of Medicine, Combined Military Hospital Malir /National University of Medical Sciences (NUMS) Pakistan
  • Hasham Bin Tahir Department of Medicine, Combined Military Hospital Malir /National University of Medical Sciences (NUMS) Pakistan
  • Imran Ali Department of Medicine, Combined Military Hospital Malir /National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i5.6958

Keywords:

Anti-Hypertensives, Cardiovascular disease, Smoking, Statins.

Abstract

Objective: To calculate 10-year Atherosclerotic Cardiovascular Disease risk score in outdoor department of a tertiary care hospital and identify individuals at high risk of cardiovascular disease.

Study Design: Cross-sectional study.

Place and Duration of Study: Combined Military Hospital, Malir, Pakistan, from Oct 2020 to Mar 2021.

Methodology: 116 patients presenting to Out-Patient Department of General Medicine of CMH, Malir, Pakistan, without previous evidence of cardiovascular disease were included. Previous history of diabetes, smoking, use of anti-hypertensives, Aspirin and statins was recorded. Systolic and diastolic blood pressures, waist circumference, HbA1c, fasting blood sugar, fasting LDL, HDL and total cholesterol were tested for each patient. 10-year ASCVD risk score was calculated using online ASCVD Risk Estimator calculator.

Results: Mean age of the patients was 58.6±9.92 years with 62.1% being males and 37.9% being females. Mean 10-year ASCVD risk score was 13.37±7.1, of which 21 patients (18.1%) had Very High, 66(56.9%) had Intermediate and 29(25%) had Low 10-year ASCVD risk score. Among Very High cases, 80.9% were males, all were in age group 50-79 years, 61.9% were diabetic, 33.3% were smokers and 66.7% were obese.

Conclusion: A very high percentage of study group had Intermediate or Very High 10-year ASCVD risk score. Identifying those individuals at high risk early and controlling the modifiable risk factors can help lessen the morbidity and mortality associated with cardiovascular diseases.

Downloads

Download data is not yet available.

References

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019; 139(10): e56-e528.

http://doi.org/10.1161/CIR.0000000000000659

Loscalzo J. Approach to the patient with possible cardiovascular disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 19th ed. New Dehli, India: McGraw-Hill; 2015. p. 1439-1441.

Whayne TF, Saha SP, Quevedo K, Mukherjee D. Optimal medical therapy for coronary artery disease in 2011 - perspectives from the STICH trial. Cardiovasc Hematol Agents Med Chem 2011; 9(4): 269-276.

http://doi.org/10.2174/187152511797264628

Guirguis-Blake JM, Evans CV, Senger CA, O’Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med 2016; 164(12): 804-813. http://doi.org/10.7326/M15-2113

D'Agostino RB, Pencina MJ, Massaro JM, Coady S. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart 2013; 8(1): 11-23.

http://doi.org/10.1016/j.gheart.2013.01.001

Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129(25 Suppl 2): S49-73. http://doi.org/10.1161/01.cir.0000437741.48606.98

Menon VP, Edathadathil F, Sathyapalan D, Moni M, Don A, Balachandran S, et al. Assessment of 2013 AHA/ACC ASCVD risk scores with behavioral characteristics of an urban cohort in India: preliminary analysis of Noncommunicable disease initiatives and research at Amrita (NIRAM) study. Medicine 2016; 95(49): e5542.

http://doi.org/10.1097/MD.0000000000005542

Zhang M, Jiang Y, Wang LM, Li YC, Huang ZJ, Li JH, et al. Prediction of 10-year atherosclerotic cardiovascular disease risk among adults aged 40-79 years in China: a nationally representative survey. Biomed Environ Sci 2017; 30(4): 244-254. http://doi.org/10.3967/bes2017.033

American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 2021; 44(Suppl 1): S15-33.

http://doi.org/10.2337/dc21-S002

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-3104. http://doi.org/10.1093/eurheartj/ehy339

American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care 2020; 43(Suppl 1): S66-76.

http://doi.org/10.2337/dc20-S006

ACC/AHA. ASCVD risk estimator + [Internet]. Available from: https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/ (Accessed on March 15, 2021)

Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014; 129(25 Suppl 2): S102-1038. http://doi.org/10.1161/01.cir.0000437739.71477.ee

WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019; 7(10): e1332-1345.

http://doi.org/10.1016/S2214-109X(19)30318-3

Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017; 70(1): 1-25. http://doi.org/10.1016/j.jacc.2017.04.052

Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol 2013; 61(16): 1736-1743. http://doi.org/10.1016/j.jacc.2012.12.039

Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-intolerant subjects with cardiovascular disease (TRANSCEND) and the ongoing telmisartan alone and in combination with ramipril global end point trial (ONTARGET). Circulation 2012; 126(8): 934-941. http://doi.org/10.1161/CIRCULATIONAHA.112.096826

Twig G, Yaniv G, Levine H, Leiba A, Goldberger N, Derazne E, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. N Engl J Med 2016; 374(25): 2430-2440. http://doi.org/10.1056/NEJMoa1503840

Held C, Iqbal R, Lear SA, Rosengren A, Islam S, Mathew J, et al. Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. Eur Heart J 2012; 33(4): 452-466. http://doi.org/10.1093/eurheartj/ehr432

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388(10059): 2532-2561. http://doi.org/10.1016/S0140-6736(16)31357-5

Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther 2011; 5: 325-80.

http://doi.org/10.2147/DDDT.S13545

Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017; 357: j2099.

http://doi.org/10.1136/bmj.j2099

Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017; 3(6): CD006887.

http://doi.org/10.1002/14651858.CD006887.pub3

Wang H, Sun Y, Wang S, Tao Y, Zhang L. Comparisons of the Framingham and ASCVD risk scores for coronary heart disease risk prediction in Chinese men. Int J Cardiol 2018; 266: 269-273. http://doi.org/10.1016/j.ijcard.2018.01.144

Ashraf T, Achakzai AS, Farooq F, Memon MA, Mengal N, Abbas KY, et al. Estimating risk of atherosclerotic cardiovascular diseases in non-atherosclerotic Pakistani patients: study conducted at National Institute of Cardiovascular Diseases, Karachi, Pakistan. J Pak Med Assoc 2017; 67(4): 494-498.

Downloads

Published

31-10-2024

Issue

Section

Original Articles

How to Cite

1.
Khan HW, Imran M, Khan S, Athar MH, Tahir HB, Ali I. 10-Year Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Calculation   in Out-Patient Department. Pak Armed Forces Med J [Internet]. 2024 Oct. 31 [cited 2024 Dec. 3];74(5):1255-9. Available from: https://pafmj.org/PAFMJ/article/view/6958